Boston Scientific (BSX) Free Cash Flow (2009 - 2026)

Boston Scientific (BSX) has 18 years of Free Cash Flow data on file, last reported at $171.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 51.69% year-over-year to $171.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 billion (up 15.3% YoY), and the FY2025 full-year result was $3.7 billion, up 38.3% from the prior year.
• Free Cash Flow slipped to $171.0 million in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $1.2 billion in Q4 2024 to a low of -$179.0 million in Q1 2022.
• A 5-year average of $541.4 million and a median of $515.0 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow tumbled 185.65% in 2022 and soared 2460.0% in 2025, its largest moves.
• Tracing BSX's Free Cash Flow over 5 years: stood at $595.0 million in 2022, then rose by 15.97% to $690.0 million in 2023, then jumped by 70.87% to $1.2 billion in 2024, then decreased by 14.08% to $1.0 billion in 2025, then sank by 83.12% to $171.0 million in 2026.
• Business Quant data shows BSX's Free Cash Flow at $171.0 million in Q1 2026, $1.0 billion in Q4 2025, and $1.2 billion in Q3 2025.